Search by Drug Name or NDC
NDC 59148-0102-80 Abilify Asimtufii 720 mg/2.4mL Details
Abilify Asimtufii 720 mg/2.4mL
Abilify Asimtufii is a INTRAMUSCULAR INJECTION, SUSPENSION, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Otsuka America Pharmaceutical, Inc. The primary component is ARIPIPRAZOLE.
MedlinePlus Drug Summary
Aripiprazole extended-release injection (Abilify Asimtufii, Abilify Maintena, Aristada, Aristada Initio) is used alone or in combination with other aripiprazole preparations to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Aripiprazole extended-release injection (Abilify Asimtufii, Abilify Maintena) is also used for the ongoing treatment of people with bipolar I disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Aripiprazole is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.
Related Packages: 59148-0102-80Last Updated: 04/21/2024
MedLinePlus Full Drug Details: Aripiprazole Injection
Product Information
| NDC | 59148-0102 |
|---|---|
| Product ID | 59148-102_1a7e9b25-5e3a-49ad-8bb8-86c480399ff8 |
| Associated GPIs | |
| GCN Sequence Number | 084704 |
| GCN Sequence Number Description | aripiprazole SUSER SYR 720 MG/2.4 INTRAMUSC |
| HIC3 | H7X |
| HIC3 Description | ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED |
| GCN | 54058 |
| HICL Sequence Number | 024551 |
| HICL Sequence Number Description | ARIPIPRAZOLE |
| Brand/Generic | Brand |
| Proprietary Name | Abilify Asimtufii |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Aripiprazole |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SUSPENSION, EXTENDED RELEASE |
| Route | INTRAMUSCULAR |
| Active Ingredient Strength | 720 |
| Active Ingredient Units | mg/2.4mL |
| Substance Name | ARIPIPRAZOLE |
| Labeler Name | Otsuka America Pharmaceutical, Inc |
| Pharmaceutical Class | Atypical Antipsychotic [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA217006 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 59148-0102-80 (59148010280)
| NDC Package Code | 59148-102-80 |
|---|---|
| Billing NDC | 59148010280 |
| Package | 1 SYRINGE in 1 CARTON (59148-102-80) / 2.4 mL in 1 SYRINGE |
| Marketing Start Date | 2023-04-27 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |